Scientists have made a major breakthrough in the fight against malaria, identifying a unique protein that is essential for the parasite's survival and transmission. The discovery, made by an international team of researchers, centres on a molecule called Aurora-related kinase 1 (ARK1), which acts as a 'traffic controller' during the parasite's cell division and growth process.
The team, which includes researchers from the University of Nottingham, National Institute of Immunology (NII) in India, University of Groningen, and the Francis Crick Institute, believes that targeting ARK1 could lead to the development of new antimalaria drugs. The study was published in Nature Communications.
According to a release by University of Nottingham, Malaria remains one of the world's deadliest diseases, caused by Plasmodium parasites that replicate rapidly within humans and mosquitoes. Understanding how these parasites divide and multiply is crucial to stopping the disease.
Unlike human cells, the malaria parasite divides and grows in a unique, atypical way. The research team discovered that ARK1 is responsible for organising the 'spindle', the molecular machinery that pulls genetic material apart to create new parasites.
When the researchers turned off ARK1 in the lab, the results were striking. The parasite could no longer form proper spindles, causing its replication to fail, and crucially, parasites lacking ARK1 could not complete their development both in the host and the mosquito, effectively stopping the disease from being passed on.
"The name 'Aurora' refers to the Roman goddess of dawn, and we believe this protein truly heralds a new beginning in our understanding of malaria cell biology," said Dr Ryuji Yanase first author of the study from the School of Life Sciences at the University of Nottingham.
"Plasmodium divides via distinct processes in the human and mosquito host, it was well and truly a team effort, which allowed us to appreciate the role of ARK1 almost simultaneously in the two hosts and shed light on novel aspects of parasite biology, " said Annu Nagar and Dr Pushkar Sharma from the Biotechnology Research and Innovation Council (BRIC)-NII, New Delhi.
"What makes this discovery so exciting is that the malaria parasite's 'Aurora' complex is very different from the version found in human cells. This divergence is a huge advantage," Professor Tewari added. "It means we can potentially design drugs that target the parasite's ARK1 specifically, turning the lights out on malaria without harming the patient."
This study maps out the unconventional molecular machinery of the parasite, providing a "blueprint" for future drug discovery efforts aimed at breaking the cycle of malaria transmission.
